Abstract
Alzheimer’s disease is a neurodegenerative disorder leading to dementia. Scientific efforts in the last decade focused mainly on understanding pathophysiology of disease and possible pharmacological approach to alleviate cognitive decline symptoms. Amyloid cascade hypothesis though criticized, remains the leading hypothesis to understand pathogenic mechanisms of cognitive decline. Intriguingly, changes of metabolic activity of cortical neurons are associated with reduced or absent sensitivity to insulin in Alzheimer’s disease brain. Insulin is a multipotent hormone regulating, not only glucose levels, but also cell survival and synaptic plasticity mechanisms of neurons. Replacement of insulin might represent a new strategic approach to counteract neurodegeneration. Here we review most of the available data regarding relationship between Alzheimer’s disease and insulin and propose new direction to deepen our understanding about insulin involvement in the pathogenesis of Alzheimer’s dementia.
Keywords: Alzheimer’s disease, Diabetes mellitus, insulin, neurodegeneration amyloid-beta, tau.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Insulin and the Future Treatment of Alzheimer’s Disease
Volume: 15 Issue: 6
Author(s): Roberta Semprini, Giacomo Koch, Lorena Belli, Francesco D. Lorenzo, Mauro Ragonese, Guglielmo Manenti, Gian P. Sorice and Alessandro Martorana
Affiliation:
Keywords: Alzheimer’s disease, Diabetes mellitus, insulin, neurodegeneration amyloid-beta, tau.
Abstract: Alzheimer’s disease is a neurodegenerative disorder leading to dementia. Scientific efforts in the last decade focused mainly on understanding pathophysiology of disease and possible pharmacological approach to alleviate cognitive decline symptoms. Amyloid cascade hypothesis though criticized, remains the leading hypothesis to understand pathogenic mechanisms of cognitive decline. Intriguingly, changes of metabolic activity of cortical neurons are associated with reduced or absent sensitivity to insulin in Alzheimer’s disease brain. Insulin is a multipotent hormone regulating, not only glucose levels, but also cell survival and synaptic plasticity mechanisms of neurons. Replacement of insulin might represent a new strategic approach to counteract neurodegeneration. Here we review most of the available data regarding relationship between Alzheimer’s disease and insulin and propose new direction to deepen our understanding about insulin involvement in the pathogenesis of Alzheimer’s dementia.
Export Options
About this article
Cite this article as:
Semprini Roberta, Koch Giacomo, Belli Lorena, Lorenzo D. Francesco, Ragonese Mauro, Manenti Guglielmo, Sorice P. Gian and Martorana Alessandro, Insulin and the Future Treatment of Alzheimer’s Disease, CNS & Neurological Disorders - Drug Targets 2016; 15 (6) . https://dx.doi.org/10.2174/1871527315666160518123049
DOI https://dx.doi.org/10.2174/1871527315666160518123049 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Vitamin D and Stroke: Promise for Prevention and Better Outcome
Current Vascular Pharmacology Differential Cued-Stroop Performance in Cognitively Asymptomatic Older Adults with Biomarker-Identified Risk for Alzheimer’s Disease: A Pilot Study
Current Alzheimer Research New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Thematic Issue: Vascular Dysfunction in Obesity and Insulin Resistance)
Current Vascular Pharmacology Quinoline: An Attractive Scaffold in Drug Design
Mini-Reviews in Medicinal Chemistry Neurotrophins Role in Depression Neurobiology: A Review of Basic and Clinical Evidence
Current Neuropharmacology Editorial (Thematic Issue: The Crosstalk between Non-Pharmaceutical and Pharmaceutical Approaches to Prevention and Treatment of Chronic Diseases: Current Concepts and Perspectives)
Current Pharmaceutical Design Cognitive Impairment with Vascular Impairment and Degeneration
Current Neurovascular Research Estrogen Deprivation and Myocardial Infarction: Role of Aerobic Exercise Training, Inflammation and Metabolomics
Current Cardiology Reviews Mass Spectrometry Techniques: Principles and Practices for Quantitative Proteomics
Current Protein & Peptide Science Cardiovascular Disease Risk Among the Poor and Homeless – What We Know So Far
Current Cardiology Reviews Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Fatty Aspirin: A New Perspective in the Prevention of Dementia of Alzheimers Type?
Current Alzheimer Research Editorial (Hot Topic: Neurodegeneration: The First IBRO-Middle East Neuroscience Conference)
Current Alzheimer Research HHT in Childhood: Screening for Special Patients
Current Pharmaceutical Design White Matter Integrity in Subcortical Vascular Cognitive Impairment: A Multimodal Structural MRI Study
Current Alzheimer Research YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease
Current Neuropharmacology Phytochemicals for Drug Discovery in Alzheimer’s Disease: <i>In Silico</i> Advances
Current Pharmaceutical Design Editorial [Hot topic: Tau, Neurodegeneration and Alzheimers Disease (Guest Editor: Alejandra del Carmen Alonso)]
Current Alzheimer Research